Moderna (NASDAQ:MRNA) is hosting its third annual Science Day event today during which it will virtually present advances in its platform science and vaccines. Highlights:
T7 RNA polymerase engineered not to produce
double-stranded RNA impurities (a technical issue in the production of
mRNA therapeutics).
Update on research in delivery science to optimize
its lipid nanoparticles, specifically, an engineered lipid that
enhances its interactions with mRNA. It will be used with candidate
mRNA-3745 for glycogen storage disease type 1a.
Company’s mRNA platform enabling rapid design and
clinical testing of HIV-1 vaccine (designed to deliver an engineered HIV
immunogen).
Pipeline consists of 23 mRNA candidates. 13 clinical trials in process.
https://seekingalpha.com/news/3579508-moderna-highlights-pipeline-progress-science-day-event
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.